Shares of ACADIA Pharmaceuticals (NASDAQ: ACAD ) shot through the roof today, up 30% as of this filming. In the video below, Fool health-care analyst David Williamson discusses news of some great phase 3 trial results for the company's drug Pimavanserin, which treats psychosis in patients with Parkinson's disease. David tells investors how good the results were, and what advantages this drug candidate could have over its competition if it reaches FDA approval.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities, and reasons to buy and sell today. To find out more click here to claim your copy today.